Search results
Showing 496 to 510 of 794 results for mental health
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
This quality standard covers diagnosing and managing stroke in adults (over 16). It includes diagnosis, initial management, acute-phase care, rehabilitation and long-term support for people with stroke. It describes high-quality care in priority areas for improvement.
View quality statements for QS2Show all sections
Sections for QS2
- Quality statements
- Quality statement 1: Prompt admission to specialist acute stroke units
- Quality statement 2: Intensity of stroke rehabilitation
- Quality statement 3: Access to a clinical psychologist
- Quality statement 4: Early supported discharge
- Quality statement 5: Return to work
- Quality statement 6: Regular review of rehabilitation goals
- Quality statement 7: Regular review of health and social care needs
Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
schizophrenia. The absence of PTSD symptoms in this context predicts better mental health outcomes, lower service use and improved life...
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Source guidance details Comes from guidance Common mental health problems: identification and pathways to care Number CG123
collaborative care approach involving GPs, other primary care practitioners and mental health professionals, can improve the uptake of...
their overall effectiveness in different inpatient settings (such as mental health units for older people) has not been established. The...
services involved in their care, people with both long-term physical and mental health problems, people with well-defined frailty,...
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Why this is important:- Generalised anxiety disorder (GAD) is a common mental health disorder and the results of this study will be...
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.